National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Class 1 PI3K kinase family inhibitor XL147
An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential antineoplastic activity. Class 1 PI3K kinase family inhibitor XL147 reversibly binds to class 1 PI3Ks in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K signaling pathway; this may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents including genotoxic agents and receptor tyrosine kinase inhibitors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:PI3K kinase inhibitor XL147
Code name:XL147



Previous:cladribine, Clafen, Claforan, Claravis, clarithromycin
Next:class III receptor tyrosine kinase inhibitor AC220, clindamycin/hydrocortisone lotion, Clino-San vaginal lubricant, Clinoril, clobetasol propionate

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov